Financial Analysis: Eagleford Energy (OTCMKTS:GRUSF) vs. Lonza Group (OTCMKTS:LZAGY)

Lonza Group (OTCMKTS:LZAGY – Get Free Report) and Eagleford Energy (OTCMKTS:GRUSF – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Lonza Group and Eagleford Energy, as reported by MarketBeat.com.

Earnings & Valuation

This table compares Lonza Group and Eagleford Energy”s top-line revenue, earnings per share and valuation.

Lonza Group has higher revenue and earnings than Eagleford Energy.

Profitability

This table compares Lonza Group and Eagleford Energy’s net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.0% of Lonza Group shares are held by institutional investors. Comparatively, 9.3% of Eagleford Energy shares are held by institutional investors. 0.1% of Lonza Group shares are held by company insiders. Comparatively, 23.2% of Eagleford Energy shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Lonza Group beats Eagleford Energy on 8 of the 10 factors compared between the two stocks.

About Lonza Group

(Get Free Report)

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

About Eagleford Energy

(Get Free Report)

Grown Rogue International Inc., together with its subsidiaries, produces and sells cannabis products in the United States. It offers a range of cultivars for consumers, such as indicas, sativas, and hybrids; strain-specific prepackaged flowers; and pre-roll pack products, as well as provides consulting services. The company sells its products through direct-to-retail delivery and third-party delivery, wholesalers, and processors. Grown Rogue International Inc. is headquartered in Medford, Oregon.